Liminatus Pharma, Inc. (LIMN) Form 8-K — Aug 18, 2026
Liminatus Pharma filed an 8-K announcing a 1-for-50 reverse stock split, approved by the Board on August 3, 2026 and stockholders at the August 3 annual meeting. The charter amendment becomes effective 4:01 p.m. ET on August 20, 2026, with split-adjusted trading under the existing symbol LIMN beginning August 21, 2026 on the Nasdaq Capital Market. The split is a listing-survival measure: after failing the $50 million MVLS, $15 million MVPHS, and $1.00 bid-price rules, the company was slated for delisting, appealed to the Nasdaq Hearings Panel, and was transferred to the Capital Market effective August 4, 2026.
Key figures
- New cusip
- 53271X 207
- Compliance deadline
- 2026-09-03
- Reverse split ratio
- 1-for-50
- Mvls requirement usd
- 50000000
- Split effective time
- 4:01 p.m. ET on August 20, 2026
- Minimum bid price usd
- 1
- Mvphs requirement usd
- 15000000
- Nasdaq transfer effective
- 2026-08-04
- Shares outstanding pre split
- 67160362
- Split adjusted trading start
- 2026-08-21
- Shares outstanding post split
- 1343208
- Consecutive trading days required
- 10
Price after filing
Close on the filing date to close N calendar days later (from $6.50). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.